Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Radiopharmaceuticals for the Diagnosis and Therapy of Neuroendocrine Differentiated Prostate Cancer.

Current radiopharmaceuticals - 1 Jan 2017

Giovacchini Giampiero, Giovannini Elisabetta, Riondato Mattia, Ciarmiello Andrea

Abstract excerpt

Neuroendocrine differentiation of prostate cancer (PCa) is a relatively frequent event, generally understudied, that carries important prognostic information. It is the most frequently observed during the advanced stages of disease, when PCa has lost its sensitivity to androgen deprivation therapy or to chemotherapy, moderate to diffuse bone metastatic spread dominates the imaging scenario and it is responsible...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to SST gene
Share to Neuroendocrine Tumors
Share to Phenotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Positron Emission Tomography Computed Tomography

Share to Prostatic Neoplasms

Share to Radiopharmaceuticals

Share to Somatostatin

Share to Tomography, Emission-Computed, Single-Photon

Source

Identifiers

PMID: 28034291
DOI: 10.2174/1874471009666161229123126

Genes

SST
GRP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Radiopharmaceuticals for the Diagnosis and Therapy of Neuroendocrine Differentiated Prostate Cancer.PMID 28034291Read ↗

[Neuroendocrine prostate cancer: Natural history, molecular features, therapeutic management and future directions].Semantic proximity Read ↗

Treatment-induced neuroendocrine prostate cancer and de novo neuroendocrine prostate cancer: Identification, prognosis and survival, genetic and epigenetic factorsSemantic proximity Read ↗

Targeting Key Players of Neuroendocrine Differentiation in Prostate Cancer.Semantic proximity Read ↗

The neuroendocrine phenotype in prostate cancer: basic and clinical aspects.Semantic proximity Read ↗

Targeting Key Players of Neuroendocrine Differentiation in Prostate CancerSemantic proximity Read ↗

Neuroendocrine differentiation in prostatic carcinoma.Semantic proximity Read ↗

Neuroendocrine differentiation of prostate cancer.Semantic proximity Read ↗

Phase II trial of Pembrolizumab and Lenvatinib in Advanced Neuroendocrine Prostate Cancer (PLANE-PC)Semantic proximity Read ↗

Limitations of the radiotheranostic concept in neuroendocrine tumors due to lineage-dependent somatostatin receptor expression on hematopoietic stem and progenitor cellsSemantic proximity Read ↗

Neuroendocrine cells in tumour growth of the prostate.Semantic proximity Read ↗

Clinical and Biological Features of Neuroendocrine Prostate CancerSemantic proximity Read ↗

Expression and Functional Role of Orphan Receptor GPR158 in Prostate Cancer Growth and ProgressionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.